MTIP Invests $15 Million in Caresyntax
We are delighted to announce MTIP Fund II’s eighth investment in Caresyntax, a true pioneer and leader in the fast-growing surgical software, analytics and automation industry.
MTIP invested $15 million to accelerate Caresyntax’s commercial growth and to expand its data-driven surgery platform. Together with its partners, the company unites the surgical ecosystem around its mission to make surgery safer and smarter for patients and caregivers. Co-investors include BlackRock, PFM Health Sciences LP, Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, ProAssurance, Rezayat, IPF Partners, Relyens, surgical.ai and the Founders.
The investment concluded in 2023, a year in which the company achieved over 100% growth in revenue, with a similar trajectory in 2024 driven by high demand for vendor-neutral surgery solutions. Caresyntax software tools are supporting 30,000 surgical users in more than 2,800 operating rooms (OR), improving efficiency, and reducing risk for three million surgeries per year.
Headquartered in Berlin and San Francisco, Caresyntax’s teams develop proprietary software and artificial intelligence (AI) solution to support workflows, as well as capture and analyze large volumes of data in operating rooms. The solution delivers critical support to care teams in the operating room, as well as actionable insights to a variety of stakeholders along the continuum of care, including caregivers before and after the surgery, and hospital leaders. Caresyntax also offers real-time access to outside experts through its digital platform, as well as data solutions for the insurance and medtech ecosystem.
Katrin Vatiska, Investment Partner at MTIP states: "MTIP proudly backs the forefront of surgical intelligence through our investment in Caresyntax. What drew us to Caresyntax was not only their stronghold in a rapidly expanding sector but also their unique platform approach, seamlessly integrating workflow software and data-driven solutions. This investment reflects our commitment to supporting innovative solutions that enhance patient care and empower healthcare professionals globally. Together, we're driving the future of smarter and safer surgeries, making a meaningful impact on the world.”
Bjoern von Siemens, Co-Founder and CFO at Caresyntax continues: "We are immensely grateful for the engagement that MTIP has shown supporting Caresyntax mission and technology, joining our commitment to transforming surgery. This significant investment will not only enable further growth, but also validates Caresyntax position as a market leader in our industry. We are looking forward to MTIP and its excellent team being an important and engaged part of our journey towards smarter and safer surgery."
About Caresyntax:
Caresyntax is on a mission to make surgery smarter and safer. Its vendor-neutral, enterprise surgical data platform delivers actionable insights to improve patient outcomes. The platform uses proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR. This real-world evidence can be used by the care team during a procedure and accessed by those outside the operating room. After a procedure, the Caresyntax platform provides insights that help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. Headquartered in Berlin and San Francisco, Caresyntax software is used in more than 2,800 operating rooms worldwide and supports surgical teams during three million procedures per year. For more information, visit www.caresyntax.com.
About MTIP:
MTIP is a leading Swiss-based growth equity firm investing in European healthtech companies that aim to revolutionize global healthcare. We leverage our deep sector expertise to help the founders scale up successful and sustainable digital health businesses. At MTIP, we are driven by the purpose to empower healthtech innovation with a potential to transform lives and make a meaningful impact on the world.
